Search Result

Results for "

ALK kinase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Anaplastic lymphoma kinase (ALK) (67) Akt (2) Aldehyde Dehydrogenase (ALDH) (1) Apoptosis (10) Aurora Kinase (1) Autophagy (1) c-Kit (1) c-Met/HGFR (2) Casein Kinase (1) Caspase (3) CDK (3) Checkpoint Kinase (Chk) (1) EGFR (3) ERK (1) FAK (5) HyT (2) IGF-1R (10) IKK (1) Insulin Receptor (9) Isotope-Labeled Compounds (3) JNK (2) Ligands for Target Protein for PROTAC (2) MAP3K (1) Mitochondrial Metabolism (1) Molecular Glues (1) mTOR (1) Organoid (6) p38 MAPK (1) PARP (3) Pim (1) PROTACs (7) Reactive Oxygen Species (ROS) (1) Reference Standards (7) RIP kinase (2) ROS Kinase (5) Src (1) STAT (4) TGF-beta/Smad (2) TGF-β Receptor (31) Tie (2) Trk Receptor (3) TSSK (2) VEGFR (2)
By Research Areas:	Cancer (86) Cardiovascular Disease (2) Endocrinology (2) Inflammation/Immunology (16) Metabolic Disease (12) Neurological Disease (1)

By Targets:

Anaplastic lymphoma kinase (ALK) (67)

Akt (2)

Aldehyde Dehydrogenase (ALDH) (1)

Apoptosis (10)

Aurora Kinase (1)

Autophagy (1)

c-Kit (1)

c-Met/HGFR (2)

Casein Kinase (1)

Caspase (3)

CDK (3)

Checkpoint Kinase (Chk) (1)

EGFR (3)

ERK (1)

FAK (5)

HyT (2)

IGF-1R (10)

IKK (1)

Insulin Receptor (9)

Isotope-Labeled Compounds (3)

JNK (2)

Ligands for Target Protein for PROTAC (2)

MAP3K (1)

Mitochondrial Metabolism (1)

Molecular Glues (1)

mTOR (1)

Organoid (6)

p38 MAPK (1)

PARP (3)

Pim (1)

PROTACs (7)

Reactive Oxygen Species (ROS) (1)

Reference Standards (7)

RIP kinase (2)

ROS Kinase (5)

Src (1)

STAT (4)

TGF-beta/Smad (2)

TGF-β Receptor (31)

Tie (2)

Trk Receptor (3)

TSSK (2)

VEGFR (2)

By Research Areas:

Cancer (86)

Cardiovascular Disease (2)

Endocrinology (2)

Inflammation/Immunology (16)

Metabolic Disease (12)

Neurological Disease (1)

102

Inhibitors & Agonists

Screening Libraries

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Targets Recommended: Anaplastic lymphoma kinase (ALK)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10431

SB-431542 Maximum Cited Publications 294 Publications Verification	Organoid TGF-β Receptor Apoptosis	Cancer
SB-431542 is a *TGF-β receptor kinase* inhibitor (TRKI)*. SB-431542 has inhibitory activity for ALK4, ALK5 and ALK7 with IC₅₀* values of 1 μM, 0.75 μM and 2 μM, respectively. SB-431542 also inhibits TGF-β-induced transcription, gene expression, apoptosis, and growth suppression. SB-431542 can be used for the research of cancer and signal transduction pathways .

HY-10432

A 83-01 125+ Cited Publications	Organoid TGF-β Receptor	Cancer
A 83-01 is a potent inhibitor of TGF-β type I receptor **ALK5 kinase, type I nodal receptor ALK4 and type I nodal receptor ALK7, with IC₅₀s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7**, respectively .

HY-13012

RepSox 20+ Cited Publications E-616452; SJN 2511	Organoid TGF-β Receptor	Metabolic Disease
RepSox (E-616452) is a potent and selective transforming growth factor-beta receptor I/activin like kinase 5 (TGF-β-RI/ALK5) inhibitor. RepSox inhibits ALK5 autophosphorylation with an IC₅₀ value of 4 nM. RepSox can be used for the research of obesity and associated metabolic diseases such as type 2 diabetes .

HY-15656

Ceritinib 35+ Cited Publications LDK378	Anaplastic lymphoma kinase (ALK) Insulin Receptor IGF-1R	Metabolic Disease Inflammation/Immunology Cancer
Ceritinib (LDK378) is a selective, orally bioavailable, and ATP-competitive *ALK* tyrosine kinase inhibitor with an IC₅₀ of 200 pM. Ceritinib also inhibits IGF-1R, InsR, and STK22D with IC₅₀ values of 8, 7, and 23 nM, respectively. Ceritinib shows great antitumor potency .

HY-19928

Vactosertib 5+ Cited Publications EW-7197; TEW-7197	TGF-β Receptor	Cancer
Vactosertib (EW-7197) is a potent, orally active and ATP-competitive activin receptor-like kinase 5 (ALK5) inhibitor with an IC₅₀ of 12.9 nM. Vactosertib also inhibits ALK2 and ALK4 (IC₅₀ of 17.3 nM) at nanomolar concentrations. Vactosertib has potently antimetastatic activity and anticancer effect .

HY-10432A

A 83-01 sodium 125+ Cited Publications	Organoid TGF-β Receptor	Cancer
A 83-01 sodium is a potent inhibitor of TGF-β type I receptor ALK5 kinase, *ALK4* and *ALK7, with IC₅₀s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4* and *ALK7*, respectively .

HY-15609

AZD-3463 1 Publications Verification ALK/IGF1R inhibitor	IGF-1R Anaplastic lymphoma kinase (ALK) Autophagy Apoptosis	Endocrinology Cancer
AZD-3463 (ALK/IGF1R inhibitor) is an orally active ALK/IGF1R inhibitor, with a K_i of 0.75 nM for ALK. AZD3463 induces apoptosis and autophagy in neuroblastoma cells .

HY-15656A

Ceritinib dihydrochloride 35+ Cited Publications LDK378 dihydrochloride	Anaplastic lymphoma kinase (ALK) Insulin Receptor IGF-1R	Metabolic Disease Inflammation/Immunology Cancer
Ceritinib (LDK378) dihydrochloride is a selective, orally bioavailable and ATP-competitive *ALK* tyrosine kinase inhibitor with an IC₅₀ of 200 pM. Ceritinib dihydrochloride also inhibits IGF-1R, InsR, and STK22D with IC₅₀ values of 8, 7, and 23 nM, respectively. Ceritinib dihydrochloride shows great antitumor potency .

HY-112155

MS4078 4 Publications Verification	PROTACs Anaplastic lymphoma kinase (ALK)	Cancer
MS4078 is an anaplastic lymphoma kinase (ALK) PROTAC (degrader) based on Cereblon ligand, with a K_d of 19?nM for binding affinity to ALK .

HY-15841

CEP-37440	Anaplastic lymphoma kinase (ALK) FAK	Cancer
CEP-37440 is a potent, orally active dual *FAK/ALK* inhibitor with IC₅₀ values of 2.3 nM and 3.5 nM for FAK and ALK, respectively. CEP-37440 decreases the cell proliferation by blocking the autophosphorylation kinase activity of FAK1 (Tyr 397) .

HY-13326

ASP3026 5+ Cited Publications	Anaplastic lymphoma kinase (ALK) Apoptosis ROS Kinase Caspase PARP IGF-1R STAT Akt JNK	Cancer
ASP3026 is a selective and orally active inhibitor of anaplastic lymphoma kinase (ALK). ASP3026 is a selective and oral active anaplastic lymphoma kinase (ALK) inhibitor with a IC₅₀ value of 3.5 nM. ASP3026 can inhibit the phosphorylation of IGF-1R, STAT3, AKT and JNK proteins, and induce the cleavage of caspase 3 and PARP. It also inhibited ROS and ACK. ASP3026 can be used in anti-tumor research .

HY-13464

ALK-IN-1 Brigatinib analog	Anaplastic lymphoma kinase (ALK) EGFR	Cancer
ALK-IN-1 is an orally active, blood-brain barrier-permeable *ALK* and EGFR inhibitor. ALK-IN-1 binds to and inhibits ALK kinase, ALK fusion proteins, and wild-type and mutant EGFR variants, thereby disrupting their corresponding signaling pathways. ALK-IN-1 can suppress the growth and proliferation of tumor cells and exhibits potential inhibitory activity against mutant EGFR. ALK-IN-1 can be used in the research of non-small-cell lung cancer .

HY-19928A

Vactosertib Hydrochloride 5+ Cited Publications EW-7197 Hydrochloride; TEW-7197 Hydrochloride	TGF-β Receptor	Cancer
Vactosertib Hydrochloride (EW-7197 Hydrochloride) is a potent, orally active and ATP-competitive activin receptor-like kinase 5 (ALK5) inhibitor with an IC₅₀ of 12.9 nM. Vactosertib Hydrochloride also inhibits ALK2 and ALK4 (IC₅₀ of 17.3 nM) at nanomolar concentrations. Vactosertib Hydrochloride has potently antimetastatic activity and anticancer effect .

HY-109084

Conteltinib CT-707	FAK	Cancer
Conteltinib (CT-707) is a multi-kinase inhibitor targeting FAK, ALK, and Pyk2. Conteltinib exerts significant inhibitory effect on FAK with an IC₅₀ of 1.6 nM .

HY-111482

SM 16 5 Publications Verification	TGF-β Receptor	Cardiovascular Disease Inflammation/Immunology Cancer
SM 16 is a *ALK5/ALK4* kinase inhibitor with K_is of 10 and 1.5 nM, respectively.

HY-15358

ALK inhibitor 2	Anaplastic lymphoma kinase (ALK) FAK TSSK	Cancer
ALK inhibitor 2 (compound 18) is a potent pyrimidin *ALK* inhibitor. ALK inhibitor 2 is a potent inhibitor of *testis-specific serine/threonine kinase* 2 (TSSK2; IC₅₀*=37 nM) and focal adhesion kinase* (FAK; IC₅₀=5 nM) .

HY-117887

Fidrisertib BLU-782; IPN-60130; ALK2-IN-1	TGF-β Receptor	Cancer
Fidrisertib (BLU-782) is the orally active inhibitor for *activin receptor-like kinase* 2** (ALK2) that inhibits ALK2 ^R206H, *ALK2, ALK1, ALK6, ALK3, ALK4, TGFβR2* and *ALK5* with IC₅₀s of 0.2, 0.6, 3, 24, 45, 65, 67 and 155 nM, respectively .

HY-17603

Belizatinib 1 Publications Verification TSR-011	Anaplastic lymphoma kinase (ALK) Trk Receptor	Cancer
Belizatinib (TSR-011) is an orally active, potent inhibitor of ALK and TRKA, TRKB, and TRKC, with IC₅₀ of 0.7 nM for wild-type recombinant ALK kinase.

HY-18758

IN-1130 1 Publications Verification	TGF-β Receptor	Inflammation/Immunology Cancer
IN-1130 is a highly selective transforming growth factor-β type I receptor kinase (ALK5) inhibitor with an IC₅₀ of 5.3 nM for ALK5-mediated Smad3 phosphorylation. IN-1130 inhibits ALK5 phosphorylation of casein (IC₅₀=36 nM) and p38α mitogen-activated protein kinase (IC₅₀=4.3 μM). IN-1130 suppresses renal fibrosis in obstructive nephropathy and blocks breast cancer lung metastasis .

HY-78349

A 77-01 2 Publications Verification	TGF-β Receptor	Cancer
A 77-01 is a potent inhibitor of transforming growth factor (TGF)-β type I receptor superfamily activin-like kinase ALK5 with an IC₅₀ of 25 nM .

HY-10431R

SB-431542 (Standard)	Apoptosis TGF-β Receptor Organoid Reference Standards	Cancer
SB-431542 (Standard) is the analytical standard of SB-431542. SB-431542 is a *TGF-β receptor kinase* inhibitor (TRKI)*. SB-431542 has inhibitory activity for ALK4, ALK5 and ALK7 with IC₅₀* values of 1 μM, 0.75 μM and 2 μM, respectively. SB-431542 also inhibits TGF-β-induced transcription, gene expression, apoptosis, and growth suppression. SB-431542 can be used for the research of cancer and signal transduction pathways .

HY-15357

ALK inhibitor 1 1 Publications Verification	Anaplastic lymphoma kinase (ALK) FAK TSSK	Cancer
ALK inhibitor 1 (compound 17) is a potent pyrimidin *ALK* inhibitor. ALK inhibitor 1 is a potent inhibitor of *testis-specific serine/threonine kinase* 2 (TSSK2; IC₅₀*=31 nM) and focal adhesion kinase* (FAK; IC₅₀=2 nM) .

HY-112156

MS4077	PROTACs Anaplastic lymphoma kinase (ALK)	Cancer
MS4077 is an anaplastic lymphoma kinase (ALK) PROTAC (degrader) based on Cereblon ligand, with a K_d of 37 nM for binding affinity to ALK .

HY-122856

AZ12601011 4 Publications Verification	TGF-β Receptor	Cancer
AZ12601011 is an orally active, selective TGFBR1 kinase inhibitor with an IC₅₀ of 18 nM and a K_d of 2.9 nM. AZ12601011 inhibits phosphorylation of SMAD2 via selectively inhibiting *ALK4, TGFBR1, and ALK7*. AZ12601011 inhibits mammary tumor growth .

HY-123919

TL13-112 2 Publications Verification	PROTACs Anaplastic lymphoma kinase (ALK)	Cancer
TL13-112 is a potent and selective *ALK-PROTAC* degrader and inhibits *ALK* activity with an IC₅₀ value of 0.14 nM. TL13-112 also prompts the degradation of additional kinases including Aurora A, FER, PTK2 and RPS6KA1 with IC₅₀ values of 8550 nM, 42.4 nM, 25.4 nM, and 677 nM, respectively. TL13-112 is comprised of the conjugation of Ceritinib?(HY-15656) and the Cereblon ligand of Pomalidomide (HY-10984) .

HY-122582

TL13-12	PROTACs Anaplastic lymphoma kinase (ALK)	Cancer
TL13-12 is a potent and selective *ALK-PROTAC* degrader and inhibits *ALK* activity with an IC₅₀ value of 0.69 nM. TL13-12 also prompts the degradation of additional kinases including Aurora A, FER, PTK2, and RPS6KA1 with IC₅₀ values of 13.5 nM, 5.74 nM, 18.4 nM, and 65 nM, respectively. TL13-12 is comprised of the conjugation of TAE684 (HY-10192) and the Cereblon ligand of Pomalidomide (HY-10984) .

HY-19990

ALK kinase inhibitor-1	Anaplastic lymphoma kinase (ALK)	Cancer
ALK kinase inhibitor-1 is an anaplastic lymphoma kinase (ALK) inhibitor extracted from patent US20130261106A1 compound I-202 .

HY-136773

KER047 ALK2-IN-4	TGF-β Receptor	Metabolic Disease
KER047 (ALK2-IN-4) is a potent activin receptor-like kinase-2 (ALK2) inhibitor. KER047 can be used for the research of metabolic disease, such as fibrodysplasia ossificans progressiva (FOP).

HY-151289

ALK5-IN-34	TGF-β Receptor TGF-beta/Smad	Cancer
ALK5-IN-34 is an selective orally active activin receptor-like kinase (ALK) inhibitor. ALK5-IN-34 can inhibit the activity of ALK5-IN-34 with an IC₅₀ value of ≤10 nM. ALK5-IN-34 also has inhibitory of tumor growth and can be used for the research of proliferative diseases, such as cancer .

HY-19628

OD36	RIP kinase TGF-β Receptor	Inflammation/Immunology
OD36 is a RIPK2 inhibitor with an IC₅₀ of 5.3 nM. OD36 is a macrocyclic inhibitor with potent binding to the *ALK2* kinase ATP pocket. OD36 shows ALK2-directed activity with K_Ds of 37 nM .

HY-16590

X-376 1 Publications Verification	Anaplastic lymphoma kinase (ALK) c-Met/HGFR	Cancer
X-376 is a potent and highly specific *ALK* tyrosine kinase inhibitor (TKI) (IC₅₀=0.61 nM). X-376 is a less potent inhibitor of MET (IC₅₀=0.69 nM). X-376 displays potent anti-tumor activity .

HY-135366

HPN-01	IKK	Inflammation/Immunology
HPN-01 is a potent and selective IKK inhibitor, with pIC₅₀ values of 6.4, 7.0 and <4.8 for IKK-α, IKK-β and IKK-ε, respectively. HPN-01 displays greater 50-fold selectivity over a panel of more than 50 other kinases, including ALK5, CDK-2, EGFR, ErbB2, GSK3β, PLK1, Src, and VEGFR-2 .

HY-152845

Ficonalkib	Anaplastic lymphoma kinase (ALK)	Cancer
Ficonalkib is a potent inhibitor of Anaplastic lymphoma kinase (ALK), the *tyrosine kinase* receptor**. Ficonalkib, can be used as an antineoplastic agent .

HY-10432R

A 83-01 (Standard)	Reference Standards TGF-β Receptor	Cancer
A 83-01 (Standard) is the analytical standard of A 83-01 (HY-10432). This product is intended for research and analytical applications. A 83-01 is a potent inhibitor of TGF-β type I receptor **ALK5 kinase, type I nodal receptor ALK4 and type I nodal receptor ALK7, with IC₅₀s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7**, respectively .

HY-137918

TGF-βRI inhibitor 3	Src TGF-β Receptor Anaplastic lymphoma kinase (ALK)	Others
TGF-βRI inhibitor 3 (Compound 9ac) is a selective TGF-β inhibitor. TGF-βRI inhibitor 3 can effectively inhibit the TGF-β signaling pathway. TGF-βRI inhibitor 3 has IC₅₀ values of 13 μM and 0.63 μM for c-Src kinase and *ALK5* kinase, respectively .

HY-125851

TP-008	TGF-β Receptor	Inflammation/Immunology
TP-008, a chemical probe, is a potent, selective and orally active (Activin-Like Kinase 5) ALK5 inhibitor with pIC₅₀ and pEC₅₀ values of 7.6 and 6.63, respectively. TGFβRI-IN-2 can produce observed cardiac toxicity in vivo at high dose .

HY-160520

ALK-IN-28	Anaplastic lymphoma kinase (ALK)	Cancer
ALK-IN-28 (compound 22) is an inhibitor of anaplastic lymphoma kinase (ALK) .

HY-156432

ALK-IN-26	Anaplastic lymphoma kinase (ALK) mTOR PARP Caspase	Cancer
ALK-IN-26 is an ALK inhibitor with IC₅₀ value of 7.0 μM for ALK tyrosine kinase. ALK-IN-26 has good pharmacokinetic properties and blood-brain barrier (BBB) permeability. ALK-IN-26 can induce apoptosis, autophagy and necrosis. ALK-IN-26 can be used in glioblastoma studies .

HY-12215S2

Deulorlatinib PF-06463922-d₃-1	Isotope-Labeled Compounds	Cancer
Deulorlatinib (compound A), a deuterated derivative of Lorlatinib (HY-12215), is a potent inhibitor of tyrosine kinase demonstrating the potential for the research of ALK-positive advanced NSCLC .

HY-155939

M4K2163 dihydrochloride	TGF-β Receptor	Cancer
M4K2163 dihydrochloride is a potent, selective, blood-brain barrier (BBB) permeable activin receptor-like kinase-2 (ALK2) inhibitor, with an IC₅₀ of 19 nM. M4K2163 dihydrochloride can be used in the research of diffuse intrinsic pontine glioma (DIPG) .

HY-118528A

TP0427736 hydrochloride 2 Publications Verification	TGF-β Receptor	Endocrinology
TP0427736 hydrochloride is a potent inhibitor of *ALK5* kinase activity with an IC₅₀ of 2.72 nM and this effect is 300-fold higher than the inhibitory effect on ALK3 (IC₅₀=836 nM). TP0427736 hydrochloride also inhibits Smad2/3 phosphorylation in A549 cells induced by TGF-β1 with an IC₅₀ value of 8.68 nM. TP0427736 hydrochloride can be used for the research of androgenic alopecia (AGA) .

HY-19628A

OD36 hydrochloride	RIP kinase TGF-β Receptor	Inflammation/Immunology
OD36hydrochloride is a RIPK2 inhibitor with an IC₅₀ of 5.3 nM. OD36 hydrochloride is a macrocyclic inhibitor with potent binding to the *ALK2* kinase ATP pocket. OD36 hydrochloride shows ALK2-directed activity with K_Ds of 37 nM .

HY-169481

AP-1	PROTACs Anaplastic lymphoma kinase (ALK)	Cancer
AP-1 is a PROTAC targeting anaplastic lymphoma kinase (ALK). AP-1 is composed of PROTAC target protein ligand CS-1243648 (HY-169482) (red part), E3 ligase ligand Pomalidomide (HY-10984) (blue part) and PROTAC Linker 2-(Tert-Butoxy)-2-oxoacetic acid (HY-W687662) (black part) .

HY-111752

*EML4-ALK* kinase inhibitor 1**	Anaplastic lymphoma kinase (ALK)	Cancer
EML4-ALK kinase inhibitor 1 is a potent orally active inhibitor of echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase *(EML4-ALK), with an IC₅₀* of 1 nM .

HY-E70714

EML4 ALK F1174L Recombinant Human Active Protein Kinase	Anaplastic lymphoma kinase (ALK)	Cancer
EML4-ALK is a fusion-type protein tyrosine kinase produced through gene rearrangement. EML4-ALK can be used for the study of non-small cell lung carcinoma (NSCLC) and neuroblastoma (NB). EML4-ALK has multiple mutants. EML4 ALK F1174L Recombinant Human Active Protein Kinase is a recombinant EML4 ALK F1174L protein that can be used to study EML4 ALK F1174L-related functions .

HY-160172

ALK/ROS1-IN-4	Anaplastic lymphoma kinase (ALK) ROS Kinase	Cancer
ALK/ROS1-IN-4 (example 13) is a dual inhibitor of *ALK* and ROS1 kinase .

HY-15656S

Ceritinib-d7 LDK378 d₇	Isotope-Labeled Compounds Anaplastic lymphoma kinase (ALK) Insulin Receptor IGF-1R	Metabolic Disease Inflammation/Immunology Cancer
Ceritinib (LDK378)-d₇ is a deuterium labeled Ceritinib (HY-15656). Ceritinib is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor . Ceritinib is a selective, orally bioavailable, and ATP-competitive *ALK* tyrosine kinase inhibitor with an IC₅₀ of 200 pM. Ceritinib also inhibits IGF-1R, InsR, and STK22D with IC₅₀ values of 8, 7, and 23 nM, respectively. Ceritinib shows great antitumor potency .

HY-13012R

RepSox (Standard) E-616452 (Standard); SJN 2511 (Standard)	Organoid TGF-β Receptor Reference Standards	Metabolic Disease
RepSox (Standard) is the analytical standard of RepSox. This product is intended for research and analytical applications. RepSox (E-616452) is a potent and selective transforming growth factor-beta receptor I/activin like kinase 5 (TGF-β-RI/ALK5) inhibitor. RepSox inhibits ALK5 autophosphorylation with an IC50 value of 4 nM. RepSox can be used for the research of obesity and associated metabolic diseases such as type 2 diabetes .

HY-156470

*Multi-kinase-IN-6*	Trk Receptor Anaplastic lymphoma kinase (ALK) c-Kit EGFR Pim Casein Kinase Checkpoint Kinase (Chk) CDK Apoptosis	Cancer
Multi-kinase-IN-6 (compound 10e) is a multikinase inhibitor that shows good enzyme inhibitory activity against TrkA, *ALK2, c-KIT, EGFR, PIM1, CK2α, CHK1, and CDK2. Multi-kinase-IN-6 reveals antiproliferative activity against MCF7, HCT116 and EKVX with IC₅₀* values of 3.36 μM, 1.40 μM and 3.49 μM, respectively. Multi-kinase-IN-6 shows cell cycle arrest at the G1/S phase and G1 phase in MCF7 and HCT116 cells with good apoptotic effect .

HY-15656R

Ceritinib (Standard) LDK378 (Standard)	Reference Standards Anaplastic lymphoma kinase (ALK) Insulin Receptor IGF-1R	Metabolic Disease Inflammation/Immunology Cancer
Ceritinib (Standard) is the analytical standard of Ceritinib (HY-15656). This product is intended for research and analytical applications. Ceritinib is a selective, orally bioavailable, and ATP-competitive *ALK* tyrosine kinase inhibitor with an IC₅₀ of 200 pM. Ceritinib also inhibits IGF-1R, InsR, and STK22D with IC₅₀ values of 8, 7, and 23 nM, respectively. Ceritinib shows great antitumor potency .

Cat. No.	Product Name

HY-L196

Protein Kinase Compound Library

4,332 compounds

Protein Kinases (PTKs) are a class of phosphotransferases that phosphorylate proteins. Protein kinases participate in many signal transduction pathways including those involved with growth, differentiation, and cell division. Protein kinase not only plays an important role in the process of cell activation, but also its abnormal expression is closely related to the pathogenesis of many diseases. So far, the protein kinase family has become one of the most important drug targets. The most common drug targets include ALK, B-Raf, BCR-Abl, EGFR, and VEGFR.

MCE designs a unique collection of 4,332 bioactive compounds targeting protein kinases, which is an important tool for the development of drug targeting protein kinases.

HY-L016

Protein Tyrosine Kinase Compound Library

1,578 compounds

Protein tyrosine kinases (PTKs) are key signaling molecules and important drug targets. Two classes of PTKs are present in cells: the transmembrane receptor PTKs (RTKs) and the nonreceptor PTKs. The RTK family includes the receptors for insulin and for many growth factors, such as EGFR, FGFR, PDGFR, VEGFR, and NGFR. RTKs are transmembrane glycoproteins that are activated by the binding of their ligands, and they transduce the extracellular signal to the cytoplasm by phosphorylating tyrosine residues on the receptors themselves (autophosphorylation) and on downstream signaling proteins. Their principal functions of PTKs involve the regulation of multicellular aspects of the organism. Cell to cell signals concerning growth, differentiation, adhesion, motility, and death are frequently transmitted through tyrosine kinases. In humans, tyrosine kinases have been demonstrated to play significant roles in the development of many disease states, including diabetes and cancers.

MCE designs a unique collection of 1,578 compounds that act as a useful tool for PTKs-related drug screening and disease research.

HY-L075

Anti-Lung Cancer Compound Library

2,886 compounds

Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers.

As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy.

MCE offers a unique collection of 2,886 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.

Species:	Human (3) Rat (1) Mouse (3) Cynomolgus (2) Canine (1)
Tag:	His (4) Avi (1) Fc (7)
Source:	HEK293 (9) Sf9 insect cells (1)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P703827

	ALK Protein, Mouse (HEK293, hFc) ALK tyrosine kinase receptor; Anaplastic lymphoma kinase; ALK;	Mouse	HEK293
	ALK Protein, Mouse (HEK293, hFc) is the recombinant mouse-derived ALK protein, expressed by HEK293, with C-hFc tag.

HY-P702715

	ALK Protein, Human (L1196M, Biotinylated, sf9, Avi) ALK; anaplastic lymphoma receptor tyrosine kinase; anaplastic lymphoma kinase (Ki 1); ALK tyrosine kinase receptor; CD246; CD246 antigen; mutant anaplastic lymphoma kinase; NBLST3;	Human	Sf9 insect cells
	ALK Protein, Human (L1196M, Biotinylated, sf9, Avi) is the recombinant human-derived ALK, expressed by Sf9 insect cells, with Avi labeled tag.

HY-P7480

	ALK-1 Protein, Human (HEK293, Fc) rHuActivin Receptor-like kinase 1, C-Fc; ALK-1; ACVRL1; Activin Receptor-like kinase 1	Human	HEK293
	ALK-1, also known as ACVRL1, is a type I receptor for TGF-β superfamily with 2 ligands, BMP9 and BMP10. ALK-1 is predominantly expressed in endothelial cells and plays a critical role in regulating developmental and pathological angiogenesis. ALK-1 Protein, Human (97a.a, HEK293, Fc) is produced in HEK293 cells with a C-Terminal Fc-tag. It consists of 97 amino acids (D22-Q118).

HY-P7481

	ACVRL1/ALK1 Protein, Mouse (HEK293, Fc) rMuActivin Receptor-like kinase 1, C-Fc; ALK-1; ACVRL1; Activin Receptor-like kinase 1	Mouse	HEK293
	ALK-1, also known as ACVRL1, is a type I receptor for TGF-β superfamily with 2 ligands, BMP9 and BMP10. ALK-1 is predominantly expressed in endothelial cells and plays a critical role in regulating developmental and pathological angiogenesis. ACVRL1/ALK1 Protein, Mouse (HEK293, Fc) is produced in HEK293 cells with a C-Terminal Fc-tag. It consists of 97 amino acids (D23-P119).

HY-P72818

	ALK-1 Protein, Human (HEK293, His) Serine/threonine-protein kinase receptor R3; SKR3; ALK-1; TSR-I; ACVRL1	Human	HEK293
	ALK-1, also known as ACVRL1, is a type I receptor for TGF-β superfamily with 2 ligands, BMP9 and BMP10. ALK-1 is predominantly expressed in endothelial cells and plays a critical role in regulating developmental and pathological angiogenesis. ALK-1 Protein, Human (HEK293, His) is produced in HEK293 cells with a C-Terminal His-tag. It consists of 118 amino acids (M1-Q118).

HY-P75516

	ALK-1 Protein, Canine (HEK293, Fc) Serine/threonine-protein kinase receptor R3; SKR3; ALK-1; TSR-I; ACVRL1	Canine	HEK293
	ALK-1, also known as ACVRL1, is a type I receptor for TGF-β superfamily with 2 ligands, BMP9 and BMP10. ALK-1 is predominantly expressed in endothelial cells and plays a critical role in regulating developmental and pathological angiogenesis. ALK-1 Protein, Canine (HEK293, Fc) is produced in HEK293 cells with a C-Terminal Fc-tag. It consists of 119 amino acids (M1-K119).

HY-P75569

	ALK-1 Protein, Cynomolgus (HEK293, His) Serine/threonine-protein kinase receptor R3; SKR3; ALK-1; TSR-I; ACVRL1	Cynomolgus	HEK293
	ALK-1, also known as ACVRL1, is a type I receptor for TGF-β superfamily with 2 ligands, BMP9 and BMP10. ALK-1 is predominantly expressed in endothelial cells and plays a critical role in regulating developmental and pathological angiogenesis. ALK-1 Protein, Cynomolgus (HEK293, His) is produced in HEK293 cells with a C-Terminal His-tag. It consists of 118 amino acids (D22-Q118).

HY-P75570

	ALK-1 Protein, Cynomolgus (HEK293, Fc) Serine/threonine-protein kinase receptor R3; SKR3; ALK-1; TSR-I; ACVRL1	Cynomolgus	HEK293
	ALK-1, also known as ACVRL1, is a type I receptor for TGF-β superfamily with 2 ligands, BMP9 and BMP10. ALK-1 is predominantly expressed in endothelial cells and plays a critical role in regulating developmental and pathological angiogenesis. ALK-1 Protein, Cynomolgus (HEK293, Fc) is produced in HEK293 cells with a C-Terminal Fc-tag. It consists of 118 amino acids (M1-Q118).

HY-P72820

	ALK-1 Protein, Rat (HEK293, His-Fc) Serine/threonine-protein kinase receptor R3; SKR3; ALK-1; TSR-I; ACVRL1	Rat	HEK293
	ALK-1, also known as ACVRL1, is a type I receptor for TGF-β superfamily with 2 ligands, BMP9 and BMP10. ALK-1 is predominantly expressed in endothelial cells and plays a critical role in regulating developmental and pathological angiogenesis. ALK-1 Protein, Rat (HEK293, His-Fc) is produced in HEK293 cells with a C-Terminal His-tag and a C-Terminal Fc-tag.

HY-P72819

	ACVRL1/ALK1 Protein, Mouse (HEK293, His-Fc) Serine/threonine-protein kinase receptor R3; SKR3; ALK-1; TSR-I; ACVRL1	Mouse	HEK293
	ALK-1, also known as ACVRL1, is a type I receptor for TGF-β superfamily with 2 ligands, BMP9 and BMP10. ALK-1 is predominantly expressed in endothelial cells and plays a critical role in regulating developmental and pathological angiogenesis. ACVRL1/ALK1 Protein, Mouse (HEK293, His-Fc) is produced in HEK293 cells with a C-Terminal His-tag and a C-Terminal Fc-tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-12215S2

Deulorlatinib
Deulorlatinib (compound A), a deuterated derivative of Lorlatinib (HY-12215), is a potent inhibitor of tyrosine kinase demonstrating the potential for the research of ALK-positive advanced NSCLC .

HY-15656S

Ceritinib-d7

Ceritinib (LDK378)-d₇ is a deuterium labeled Ceritinib (HY-15656). Ceritinib is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor . Ceritinib is a selective, orally bioavailable, and ATP-competitive ALK tyrosine kinase inhibitor with an IC₅₀ of 200 pM. Ceritinib also inhibits IGF-1R, InsR, and STK22D with IC₅₀ values of 8, 7, and 23 nM, respectively. Ceritinib shows great antitumor potency .

HY-13012S

RepSox-d5
RepSox-d₅ (E-616452-d₅) is the deuterium labeled RepSox (HY-13012). RepSox (E-616452) is a potent and selective transforming growth factor-beta receptor I/activin like kinase 5 (TGF-β-RI/ALK5) inhibitor. RepSox inhibits ALK5 autophosphorylation with an IC₅₀ value of 4 nM. RepSox can be used for the research of obesity and associated metabolic diseases such as type 2 diabetes .

Host:	Rabbit (5)
Reactivity:	Human (5) Rat (4) Mouse (4)
Application:	IHC-P (2) ICC/IF (2) IP (1) IHC-F (1) WB (5) FC (2) ELISA (1)
Isotype:	IgG (4) IgG/Kappa (1)
Conjugation:	Non-conjugated (5) Biotin (1)
Clonality:	Monoclonal (4) Recombinant (2)
Modification:	Unmodified (4)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P86369

	ALK/p80 Antibody (YA6061) ALK; ALK tyrosine kinase receptor; Anaplastic lymphoma kinase; CD antigen CD246	WB, IHC-P, ICC/IF, IP, ELISA	Human
	ALK/p80 Antibody (YA6061) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ALK/p80.

HY-P82712

	ALK-1 Antibody (YA2457) ACVRL1; ACVRLK1; ALK1; Serine/threonine-protein kinase receptor R3; SKR3; Activin receptor-like kinase 1; ALK-1; TGF-B superfamily receptor type I; TSR-I	WB	Human, Mouse, Rat
	ALK-1 Antibody (YA2457) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ALK-1.

HY-P82244

	Activin A Receptor Type IB Antibody (YA1989) ACVR1B; ACVRLK4; ALK4; Activin receptor type-1B; Activin receptor type IB; ACTR-IB; Activin receptor-like kinase 4; ALK-4; Serine/threonine-protein kinase receptor R2; SKR2	WB, FC	Human, Mouse, Rat
	Activin A Receptor Type IB Antibody (YA1989) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Activin A Receptor Type IB.

HY-P82244A

	Activin A Receptor Type IB Antibody (YA1989)(PBS only) ACVR1B; ACVRLK4; ALK4; Activin receptor type-1B; Activin receptor type IB; ACTR-IB; Activin receptor-like kinase 4; ALK-4; Serine/threonine-protein kinase receptor R2; SKR2	WB, FC	Human, Mouse, Rat
	Activin A Receptor Type IB Antibody (YA1989) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Activin A Receptor Type IB.

HY-P810513

	Activin A Receptor Type IB Antibody (YA9797) ACVR1B, ACVRLK4, ALK4, Activin receptor type-1B, Activin receptor type IB, ACTR-IB, Activin receptor-like kinase 4, ALK-4, Serine/threonine-protein kinase receptor R2, SKR2	WB, IHC-F, IHC-P, ICC/IF	Human, Mouse, Rat
	Activin A Receptor Type IB Antibody (YA9797) is a Rabbit-derived and non-conjugated IgG Monoclonal antibody, targeting to Activin A Receptor Type IB.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: